Secondary Drug Failure, Type 2 Diabetes
Conditions
Brief summary
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
Detailed description
The present study was undertaken to assess differences in how insulin glargine vs. pioglitazone affect: * Beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for insulin secretion (HOMA β-cell) and glucagon stimulated C-peptide test * Insulin sensitivity as measured by adiponectin, homeostasis model assessment for insulin resistance (HOMA-IR) and insulin tolerance test and * Surrogate markers of cardiovascular disease as measured by BNP, NT-pro BNP and plasma lipid profile as add-on therapy in patients with T2D and secondary drug failure. The patients' satisfaction with each treatment was also surveyed.
Interventions
DRUGpioglitazone
tablet, 30 mg, once daily, 26 weeks
DRUGinsulin glargine
subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
Sponsors
Medical Research Council
Skane County Council Research & Development Foundation
Skane University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* type 2 diabetes * inadequately controlled on 50% of maximal-dose of an insulin secretagogue and metformin
Exclusion criteria
* heart failure (NYHA II-IV)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity | 26 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Effect of pioglitazone vs. insulin glargine on BNP | 26 weeks |
Countries
Sweden
Outcome results
None listed